Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Join Medicilon at BioForward 2022 - The 'Roadmap for Growth' Life Sciences Event

2022-09-16
|
Page View:

1.pngBioForward 2022 is only one week to go! Medicilon is excited to exhibit in the conference. Medicilon European Team will be waiting at Stand 22. We are happy to meet you in person to discuss how our services and capabilities would support your current research needs and expedite your drug discovery and development programs. We look forward to seeing you soon and wish you safe trips!

Date:  Tuesday, Septemper 27, 2022 (8 AM - 6 PM) (GMT+1) 

Location: England, United Kingdom

Stand: 22

About BioForward

BioForward is OBN's 'Roadmap for Growth' Life Sciences event, designed to provide the support, skills, know-how and industry connections required to build a commercially successful business. Now in its fourth year, the event is attended by leaders and decision makers of growing R&D companies across all therapy and technological areas, along side companies who provide critical support services to emerging companies within the life sciences ecosystem. BioForward has been specifically designed for growing life sciences R&D companies, and high-quality Service Providers who can provide the critical support and advice required to help them build a commercially sustainable business.

Agenda

3.png

About Medicilon

Fully Integrated Preclinical Drug Discovery and Development Services

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. With our experience in serving domestic and foreign biomedical industries, we have built an integrated technical platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, in a bid to provide comprehensive preclinical new drug R&D for the global biomedical industry.

At Medicilon, we are dedicated to help our clients develop their research and discovery programs from initial idea all the way through the Investigational New Drug (IND) filing phase. Our services span across medicinal chemistry, biology, API, CMC, formulation, and preclinical studies. We provide flexible business models, including stand-alone Fee for Services (FFS) and fully integrated FTE services. In addition, our facilities are GLP/GMP compliant, US-FDA, China NMPA and AAALAC accredited. All study reports can be presented in SEND format, supporting dual filing of IND applications in the US, EU, and China.

18+

18+ years of experience in new drug R&D

1710+

Active clients worldwide

2800+

Newdrug discovery scientists and service personnel

81600+

Square meters of Laboratory floor space

268

Projects successfully approved with FDA, NMPA, EMA, and TGA

Services and Solutions

Drug Discovery

Medicinal Chemistry

Biology Services

CMC Services

Intermediates

APIs

Pharmaceutic Formulation

Preclinical Studies

Pharmacodynamics

Pharmacokinetics

Drug Safety Evaluation

IND Filing

One-stop Integrated Services Platform

PROTAC Drug Discovery Research Platform

Antibody-Drug Conjugate(ADC) R&D Service Platform

Nucleic Acid Drug R&D Platform

Cytokine and Biomarker Detection Platform

Flow Cytometry Technology Platform

mRNA Vaccine Bioanalysis Platform

Pharmaceutical Research CDMO Service Platform

Process Department Solid Form Screening Platform

Inhalation drug R&D platform

Skin Topical Preparation R&D

IO Pharmacodynamic Model Evaluation Platform

Cellular Immunotherapies R&D platform

Ophthalmic drug R&D platform


Share:
Relevant newsRelevant news